Literature DB >> 17583373

Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.

Cheyda Chams-Davatchi1, Nafiseh Esmaili, Maryam Daneshpazhooh, Mahin Valikhani, Kamran Balighi, Zahra Hallaji, Masoumeh Barzegari, Maryam Akhyani, S Zahra Ghodsi, Hassan Seirafi, Mohammad-Javad Tabrizi Nazemi, Hossein Mortazavi, Mostafa Mirshams-Shahshahani.   

Abstract

BACKGROUND: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts.
OBJECTIVE: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy.
METHODS: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for 1 year at the Pemphigus Research Unit.
RESULTS: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P = .047). In the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P = .007), but not between P/A and P/PC (P = .971), and P/MM and P/PC (P = .670). Side effects were not significantly different among the 4 groups. LIMITATIONS: Larger sample sizes and blind design are suggested for future studies.
CONCLUSION: The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycophenolate mofetil.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583373     DOI: 10.1016/j.jaad.2007.05.024

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  28 in total

1.  A practical approach to treating autoimmune bullous disorders with systemic medications.

Authors:  Anne Han
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

Review 2.  Seeking approval: present and future therapies for pemphigus vulgaris.

Authors:  Xuming Mao; Aimee S Payne
Journal:  Curr Opin Investig Drugs       Date:  2008-05

Review 3.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

Review 4.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

5.  [Pemphigus vulgaris. Therapy with cyclophosphamide].

Authors:  L Vanstreels; A Alkhateeb; M Megahed
Journal:  Hautarzt       Date:  2013-05       Impact factor: 0.751

6.  A case of pemphigus vulgaris associated with ulcerative colitis.

Authors:  Joo Wan Seo; Jongha Park; Jin Lee; Mi Young Kim; Hyun Ju Choi; Heui Jeong Jeong; Ji Woon Lee; So Young Jung; Woo Kyeong Kim
Journal:  Intest Res       Date:  2018-01-18

7.  Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

Authors:  Luisa Lunardon; Kathleen J Tsai; Kathleen J Propert; Nicole Fett; John R Stanley; Victoria P Werth; Donald E Tsai; Aimee S Payne
Journal:  Arch Dermatol       Date:  2012-09

Review 8.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

9.  Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF).

Authors:  Andrea Baratta; Diana Camarillo; Christine Papa; James R Treat; Aimee S Payne; Suzanne S Rozenber; Albert C Yan
Journal:  Pediatr Dermatol       Date:  2012-07-02       Impact factor: 1.588

Review 10.  [Optimizing therapy in patients with severe autoimmune blistering skin diseases].

Authors:  E Schmidt
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.